The use of ranolazine in the treatment of coronary heart disease

Cover Page

Cite item

Full Text

Abstract

The paper presents the study of a new anti-anginal drug - sodium channel inhibitor ranolazine. Considered antianginal, anti-ischemic effect of the drug. Described reduction in angina attacks, increased exercise tolerance and quality of life of patients with stable angina during treatment with ranolazine. Discusses indications, contraindications, side effects, as well as the major clinical trials of the drug ranolazine in patients with coronary heart disease.

About the authors

V. S Zadionchenko

Outpatient therapy department, Evdokimov Medical University

д-р мед. наук, проф. каф. поликлин. терапии

G. G Shehyan

Outpatient therapy department, Evdokimov Medical University

канд. мед. наук, доц. каф. поликлин. терапии

A. A Yalymov

Outpatient therapy department, Evdokimov Medical University

канд. мед. наук, ассистент каф. поликлин. терапии

S. I Varentsov

City Clinical Hospital №24, Department of Health in Moscow

зав. блоком кардиореанимации

References

  1. ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients with Stable Ischemic Heart Disease. Circulation 2012; 126: 354-471.
  2. US Food and Drug Administration. http://www.fda.gov/ohrms/doc-kets/ac/03/briefing/4012B2_01_Action%20Letter.pdf
  3. Aslam S, Gray D. Ranolazine (Ranexa) in the treatment of chronic stable angina. Adv Ther 2010; 27 (4): 193-201.
  4. Lee L, Horowitz J, Flenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004; 25: 634-41.
  5. Lopaschuk G.D, Kantor P.F, Dyck J.R.B. Optimizing cardiac metabolism: a new reference approach in the management of ischemic heart disease? Medicographia 1999; 21 (2): 109-15.
  6. Reffelmann T, Kloner R.A. Ranolazine: anti - anginal drug with further therapeutic potential. Expert Review of Cardiovascular Therapy 2010; 8 (3): 319-329.
  7. Stone P.H. Ranolazine: New Paradigm for Management of Myocardial Ischemia, Myocardial Dysfunction, and Arrhythmias. Cardiology Clinics 2008; 26 (4): 603-14.
  8. Pepine C.J, Wolff A.A. A controlled trial a novel anti - ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. Am J Cardiol 1999; 84: 46-50.
  9. Rousseau M.F, Pouleur H, Cocco G, Wolff A.F. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 2005; 95: 311-6.
  10. Bassand J-P. Clinical implications of inhibitor of the late sodium current: ranolazine. Eur Heart J 2006; 8 (Suppl. A): A14-A19.
  11. Chaitman B.R, Pepine C.J, Parker J.O et al. Combination Assessment of Ranolazine in Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial JAMA 2004; 291: 309-16.
  12. Chaitman B.R, Skettino S.L, Parker J.O et al for the MARISA Investigators. Anti - ischemic effects and long - term survival during ranolazinemonotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004; 43: 1375-82.
  13. Stone P.H, Gratsiansky N.A, Blokhin A et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006; 48 (3): 566-75.
  14. Arnold S.V, Morrow D.A, Lei Y et al. Economic impact of angina after an acute coronary syndrome: Insights from the MERLIN-TIMI 36 trial. Circ Cardiovasc Qual Outcomes 2009; 2 (4): 344-53.
  15. Melloni C, Newby L.K. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study. Expert Rev Cardiovasc Ther 2008; 6 (1): 9-16.
  16. Morrow D.A, Scirica B.M, Karwatowska-Prokopczuk E et al. Evaluation of a novel anti - ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MER- LIN)-TIMI 36 trial. Am Heart J 2006; 151 (6): 1181-9.
  17. Wilson S.R, Scirica B.M, Braunwald E еt al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double - blind, placebo - controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol 2009; 53 (17): 1510-6.
  18. Deshmukh S.H, Patel S.R, Pinassi E et al. Ranolazine improves endothelial function in patients with stable coronary artery disease. Coron Artery Dis 2009; 20 (5): 343-7.
  19. Тimmis A.D, Chaitman B.R, Grager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006; 27 (1): 42-48.

Copyright (c) 2014 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies